467 Updated efficacy and safety results for a randomized phase 2 trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P) and bevacizumab (B) in stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC): The FALCON trial

467 Updated efficacy and safety results for a randomized phase 2 trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P) and bevacizumab (B) in stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC): The FALCON trial

Saved in:
Bibliographic Details
Published in:European journal of cancer supplements Vol. 8; no. 7; p. 150
Main Authors: Garon, E.B, Neidhart, J, Neidhart, J.D, Kabbinavar, F, Gabrail, N, de Oliveira, M. Ribeiro, Lu, S.P, Balkissoon, J
Format: Journal Article
Language:English
Published: Elsevier Ltd 2010
Subjects:
Hematology, Oncology and Palliative Medicine
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:1359-6349
1878-1217
DOI:10.1016/S1359-6349(10)72174-1